In contrast, drugs that affect the Wnt pathway upstream of APC truncation have not been tested for use in cancers harboring APC mutations [16], even though one of these agents, Secreted Frizzled-Related Protein 1 (sFRP1), was found effective in preclinical tumor models [17, 18]. This evidence concerns the gene APC and neoplasm.